Effect of heparin and heparin fractions on platelet aggregation
about
Thrombotic complications in three hemodialysis patients with heparin-induced thrombocytopenia type IEighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclinHeparin modulates the conformation and signaling of platelet integrin αIIbβ3Drug-induced and drug-dependent immune thrombocytopenias.Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesClinical efficacy of heparin fractions: issues and answers.Vitrectomy for Proliferative Diabetic Retinopathy in a Patient with Heparin-Induced Thrombocytopenia.Phlegmasia cerulea dolens and its association with hypercoagulable states: case reports.Anticoagulation Therapy in Patients with Chronic Kidney Disease.Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketoneThrombosis: its role and prevention in cardiovascular events--Part I. Concepts of thrombogenesis and its prevention.Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.The artificial endotheliumHeparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling.Synergistic effect of heparin and chemotactic factor on polymorphonuclear leukocyte aggregation and degranulation.Increased sensitivity of arachidonic acid-induced platelet aggregation in the presence of carbon dioxideChanges in membrane glycoproteins of circulating platelets after coronary stent implantation.Microfluidics for simultaneous quantification of platelet adhesion and blood viscosity.The antineoplastic effect of low-molecular-weight heparins - a literature reviewStructural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.Immobilization of heparin: approaches and applications.Six years of clinical follow-up with endothelial cell-seeded small-diameter vascular grafts during coronary bypass surgery.The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: second revision. BCSH Haemostasis and Thrombosis Task ForceThe prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.Aspirin and heparin in pregnancy.Disorders of platelet function: mechanisms, diagnosis and management.Hemodynamic studies of platelet thrombosis using microfluidics.Antithrombogenic heparin-bound polyurethanes.Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents.Technical considerations for platelet aggregation and related problems.Therapeutic Concentrations of Heparin Augment Platelet Activation at the Time of Coronary Angiography.Interaction of heparin with synthetic antithrombin III peptide analogues.Immunoglobulin-sulfated polysaccharide interactions. Binding of agaropectin and heparin by human IgG proteins.Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism.Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin.Pre-analytical effects of pneumatic tube transport on impedance platelet aggregometry.Effects of glycosaminoglycans and protamine chloridrate on platelet aggregation induced by collagen and thrombin.Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate® analyser.Interaction of blood components with heparin-immobilized polyurethanes prepared by plasma glow discharge.
P2860
Q28167373-8E8658D4-3137-4E9B-8FDB-13DE58E4F29DQ28277612-D67694BC-9459-43A5-8728-268B5A3EEE8CQ30513893-897348E8-CDA7-4103-97F4-FE05D9F1E8C0Q33339739-A49BB830-F97C-41DE-88C9-65DC6AFED37EQ33399576-ECA05FD6-4017-49B8-AD1B-9E7CC6859CBEQ33411302-043D0C99-E47F-4314-8534-B73DCFB0B79DQ33430422-1FA0ECEC-ACC7-48F7-956E-4778C8B2155BQ33431317-B8CBBB03-FCE6-4293-AB66-89E505A50590Q33435357-35C9DE82-0AA0-4240-A53B-8AE8BCF001DAQ33571477-9D37DADC-7F4C-4DEE-B4AB-3823E2387D16Q34109385-D40DA8CF-9227-4A29-A5EC-5632FBAC7F09Q34396959-6E1FD175-025C-4DD7-A3FD-ADA1E653506DQ34852479-EB22BE78-4A91-4B1C-A5C0-E3A3147B7790Q35001659-E6472368-4E44-4678-8CC0-B1799F53976EQ35885740-B4ADC84E-834D-41C9-82EB-9093A728173BQ36003771-1CA216C9-C372-4D31-A1CE-6926211BFCAEQ36834635-78DFAEB7-C405-4AE8-92CC-7F77BEDC5FDAQ36841459-29076CD4-7901-4073-898B-DF5991D4A36BQ36936771-7D806DE5-925C-4F02-8E8A-A5F2925FF3C6Q37026070-D511A143-D0AD-40CF-96C7-0DB75DF65B8EQ37090287-559FA306-8A1E-4B30-A4AD-4E16F9589C0AQ37151397-8C7A23B7-8BB8-431B-A512-393AC1DCBCB9Q37232098-55E1EB78-3CDC-4D02-8633-8D60E0ED5462Q37316352-B1F7FE41-6F75-42D0-8EBC-E18645226F83Q38001453-F6C030E4-518A-4F55-8E25-FA9232907E2FQ38544097-93B45D7E-1AED-408A-A4A0-AC85DA87F3E7Q39345812-88D40BBE-2B10-47D7-B799-804BFD378510Q39359352-2661CDA5-439A-4C86-A807-63A2A3967FACQ39704582-AC9132C4-349D-431F-AC69-3F0BD2F2593AQ39799215-D42F7237-3465-4503-979B-8A2E9CA1B4F1Q40174830-5F9A803E-B5B3-4060-9DA0-22694795E026Q41720873-788258AF-B750-4302-A4AE-331341B20826Q41763091-F271E331-0438-4B9D-816A-5620ACFA5F0BQ41962619-5921DE0E-87DD-4616-BFEE-50BE99274C9FQ42000838-53742EB2-6A4F-434D-8B13-940CDFF324B8Q42829962-CC4CE091-77D5-427B-9EFB-4A331C34CE88Q43255963-03EBFE48-4291-4DFB-80EE-8AEF2A1F5951Q43537282-26A044A2-89DF-4232-8003-2DC4D7A89893Q44664771-C79D18B6-65F8-40D5-BE99-E507D19C1F7DQ45712197-4FE07E24-302D-41B1-83AA-B7B925096BA9
P2860
Effect of heparin and heparin fractions on platelet aggregation
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1980
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of heparin and heparin fractions on platelet aggregation
@en
Effect of heparin and heparin fractions on platelet aggregation.
@nl
type
label
Effect of heparin and heparin fractions on platelet aggregation
@en
Effect of heparin and heparin fractions on platelet aggregation.
@nl
prefLabel
Effect of heparin and heparin fractions on platelet aggregation
@en
Effect of heparin and heparin fractions on platelet aggregation.
@nl
P2093
P2860
P356
P1476
Effect of heparin and heparin fractions on platelet aggregation
@en
P2093
P2860
P356
10.1172/JCI109661
P407
P577
1980-01-01T00:00:00Z